Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference
NCT03302065 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38
Last updated 2024-12-02
Summary
The purpose of this study is to compare the absorption of four different inhalation products with the reference product in healthy volunteers.
Conditions
- Healthy
Interventions
- DRUG
-
Tiotropium
Sponsors & Collaborators
-
3M
collaborator INDUSTRY -
Solventum US LLC
lead INDUSTRY
Principal Investigators
-
Victoria Sessions, PhD · 3M
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-05-31
- Primary Completion
- 2016-09-30
- Completion
- 2017-01-31
More Related Trials
-
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
NCT01316380 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment
NCT02172781 ·Status: COMPLETED ·Phase: PHASE1
-
Tiotropium Respimat Pharmacokinetic Study in COPD
NCT01222533 ·Status: COMPLETED ·Phase: PHASE2
-
Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
NCT01233284 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation
NCT02172508 ·Status: TERMINATED ·Phase: PHASE4
-
Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers
NCT01309139 ·Status: COMPLETED ·Phase: PHASE1
-
Tiotropium / Respimat One Year Study in COPD.
NCT00387088 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects
NCT02172417 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172391 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02175342 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
NCT01172808 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
NCT01172821 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers
NCT02259959 ·Status: COMPLETED ·Phase: PHASE1
-
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00240435 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
NCT00152984 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
NCT00772538 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium / Respimat One-Year Study
NCT00168831 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03118765 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
NCT00776984 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02242266 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
NCT06326671 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease
NCT02177318 ·Status: COMPLETED
-
Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response
NCT06679465 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients
NCT02172534 ·Status: COMPLETED ·Phase: PHASE1
-
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
NCT02518139 ·Status: COMPLETED ·Phase: PHASE3